NCT00864604View on ClinicalTrials.gov

Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Healthy
Interventions
DRUG

Nabumetone 750 mg tablets, single dose

A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions

DRUG

Nabumetone 750 mg tablets, single dose

B: Active comparator Subjects received Teva formulated products under fed conditions

Trial Locations (1)

27560

AAIPharma Inc., AAI Clinic, Morrisville

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00864604 - Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers | Biotech Hunter | Biotech Hunter